Alzheimer’s Drug Lecanemab Works by “Switching On” the Brain’s Cleanup Cells - Summary - MDSpire
Feature

Alzheimer’s Drug Lecanemab Works by “Switching On” the Brain’s Cleanup Cells

Study reveals Fc fragment of antibody is essential for activating microglia to clear amyloid plaques

  • April 7, 2026

  • 3 min

Share

Researchers have uncovered how the Alzheimer’s drug lecanemab functions, revealing that it not only binds to amyloid plaques but also activates the brain's immune cells via the Fc fragment. This activation triggers microglia to engulf and degrade amyloid deposits, significantly influencing the efficacy of the treatment. The study highlights a specific microglial gene expression program that aids in plaque clearance while minimizing harmful effects on neural structures. The findings suggest new strategies for future Alzheimer’s therapies by focusing on immune system modulation rather than solely targeting amyloid.

Original Source(s)

Alzheimer’s Drug Lecanemab Works by “Switching On” the Brain’s Cleanup Cells

  • April 7, 2026

Related Content

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

The Hidden Diversity of Amyloid Plaques

A multimodal MSI approach reveals how plaque-associated lipid signatures differ across brain regions in Alzheimer’s disease